CAN
TEVA icon

Cetera Advisor Networks’s Teva Pharmaceuticals TEVA Stock Holding History

Cetera Advisor Networks’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$300K Buy
+21,243
New +$268K ﹤0.01% 2292
2023
Q3 		– Sell
-25,079
Closed -$189K – 2795
2023
Q2 		$189K Buy
+25,079
New +$203K ﹤0.01% 2365
2021
Q3 		– Sell
-11,191
Closed -$111K – 2046
2021
Q2 		$111K Sell
11,191
-163
-1% -$1.73K ﹤0.01% 1844
2021
Q1 		$131K Sell
11,354
-120
-1% -$1.38K ﹤0.01% 1420
2020
Q4 		$111K Sell
11,474
-754
-6% -$7.22K ﹤0.01% 1303
2020
Q3 		$110K Sell
12,228
-999
-8% -$10.6K ﹤0.01% 1191
2020
Q2 		$163K Buy
13,227
+2,461
+23% +$27.8K ﹤0.01% 1236
2020
Q1 		$97K Buy
+10,766
New +$110K ﹤0.01% 1056
2019
Q3 		– Sell
-11,219
Closed -$102K – 1241
2019
Q2 		$102K Buy
11,219
+613
+6% +$7.39K ﹤0.01% 1146
2019
Q1 		$166K Sell
10,606
-286
-3% -$5.04K 0.01% 1081
2018
Q4 		$170K Buy
10,892
+1,055
+11% +$21.6K 0.01% 964
2018
Q3 		$209K Buy
+9,837
New +$228K 0.01% 1029
2017
Q4 		– Sell
-10,887
Closed -$195K – 1014
2017
Q3 		$195K Sell
10,887
-1,917
-15% -$43.1K 0.01% 858
2017
Q2 		$423K Buy
12,804
+6,185
+93% +$191K 0.02% 571
2017
Q1 		$210K Buy
6,619
+44
+0.7% +$1.5K 0.01% 828
2016
Q4 		$238K Sell
6,575
-4,132
-39% -$165K 0.01% 735
2016
Q3 		$493K Buy
10,707
+3,643
+52% +$190K 0.02% 586
2016
Q2 		$357K Sell
7,064
-1,212
-15% -$64.5K 0.02% 562
2016
Q1 		$445K Buy
8,276
+167
+2% +$9.8K 0.03% 475
2015
Q4 		$535K Buy
8,109
+258
+3% +$15.9K 0.03% 412
2015
Q3 		$444K Sell
7,851
-504
-6% -$32.7K 0.03% 457
2015
Q2 		$518K Hold
8,355
– – 0.03% 446
2015
Q1 		$518K Buy
8,355
+65
+0.8% +$3.78K 0.03% 448
2014
Q4 		$482K Sell
8,290
-697
-8% -$38.8K 0.03% 457
2014
Q3 		$483K Sell
8,987
-1,372
-13% -$72.7K 0.03% 460
2014
Q2 		$539K Buy
10,359
+169
+2% +$8.64K 0.04% 435
2014
Q1 		$538K Sell
10,190
-289
-3% -$13.4K 0.04% 412
2013
Q4 		$420K Sell
10,479
-1,987
-16% -$78.2K 0.03% 461
2013
Q3 		$474K Buy
12,466
+1,439
+13% +$56.1K 0.04% 366
2013
Q2 		$436K Buy
+11,027
New +$429K 0.04% 344

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Cetera Advisor Networks's TEVA Position: Q1 2024 in Review

Cetera Advisor Networks opened a new position in Teva Pharmaceuticals (TEVA) in Q1 2024: 21,243 shares worth $300K. The stake represents ﹤0.01% of the portfolio and ranks #2292 among its holdings. This is a return to the name: Cetera Advisor Networks previously reported a position in TEVA as recently as Q2 2023.

Cetera Advisor Networks first reported a position in TEVA in Q2 2013 and has held it in 30 quarters since. The position peaked at $539K in Q2 2014. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Cetera Advisor Networks held 21,243 shares of Teva Pharmaceuticals worth $300K as of Q1 2024.
  • Teva Pharmaceuticals was a new Cetera Advisor Networks position in Q1 2024.
  • Teva Pharmaceuticals made up ﹤0.01% of Cetera Advisor Networks's portfolio in Q1 2024, its #2292 holding.
  • Cetera Advisor Networks first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • Cetera Advisor Networks's Teva Pharmaceuticals position peaked at $539K in Q2 2014.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Cetera Advisor Networks's 13F filing for Q1 2024, filed 15 May 2024.